ARQT — Arcutis Biotherapeutics Inc. stock price and chart

Share this page

ARQT

$28.82-0.96%

as of close, Oct 16, 2026

☾ AH $28.82 -0.96%

Arcutis Biotherapeutics Inc.Stock · HealthcareRussell 2000 0.09%Nasdaq Composite 0.007%Russell 3000 0.004%US Stock Market 0.004%

PeersMRNALLYMDTUNHJNJTMO

Technical analysis2

Overlay lines0

Addendum charts0

Available history since Feb 5, 2020

VolumeEEEE

20202021202320252026

5.010.015.020.025.030.035.0050.0M$28.82

2026-10-16

Price$28.82

MA20$26.07

MA50$24.89

Vol7.3M

What would $1,000 invested in ARQT be worth today? →

ARQT returns: By year · By month · By week · Trailing

Key stats#

Price data

Price: $28.82
YTD price return: -0.76%
YTD total return: -0.76%
Next earnings: Oct 27, 2026
Market cap: 3.6B2020-03 1.1B2026-10 3.6B+218.8% over the window
Enterprise value: 3.7B
Shares outstanding: 125.7M2019-12 2.1M2026-06 125.7M+5826.5% over the window
52W low: $19.30
52W high: $31.77
From 52W high: -9.29%
From 52W low: +49.37%
52W range: 76%

Volume

Rel volume: 0.56×
30D volume: 3.1M
30D $ vol: 79.7M

Fundamentals

Sales (ttm): 464M2020-12 02026-06 464M
Sales/share: $3.692020-12 $0.002026-06 $3.69
EPS (ttm): $0.222019-12 -$22.782026-06 $0.22-101.0% over the window
FCF (ttm): 39.2M2018-12 -14.1M2026-06 39.2M-378.0% over the window
FCF/share: $0.312019-12 -$20.342026-06 $0.31-101.5% over the window
Book value/share: $1.752019-06 -$18.232026-06 $1.75-109.6% over the window
Net margin: 6.15%2022-09 -42864.1%2026-06 6.1%-100.0% over the window
ROE: 12.93%2020-03 -26.2%2026-06 12.9%-149.4% over the window
ROA: 5.84%2019-12 -39.2%2026-06 5.8%-114.9% over the window
Debt / equity: 0.46×2020-12 0.002026-06 0.46
Current ratio: 2.922019-12 20.332026-06 2.92-85.7% over the window

Growth (CAGR, ttm) · 10Y

Sales: +76.18%2025-06-30 → 2026-06-30263.5M → 464M (+76.1% total)+272.43%2023-03-31 → 2026-06-306.5M → 464M (+7074.6% total)n/an/a
Shares: +4.83%2025-06-30 → 2026-06-30119.9M → 125.7M (+4.8% total)+26.79%2023-06-30 → 2026-06-3061.7M → 125.7M (+103.9% total)+20.13%2021-06-30 → 2026-06-3050.2M → 125.7M (+150.2% total)n/a

Per-share growth (CAGR, ttm) · 10Y

Sales/share: +68.06%2025-06-30 → 2026-06-30$2.20 → $3.69 (+68.0% total)+198.78%2023-03-31 → 2026-06-30$0.11 → $3.69 (+3406.0% total)n/an/a
Book value/share: +51.46%2025-06-30 → 2026-06-30$1.16 → $1.75 (+51.4% total)+10.35%2023-06-30 → 2026-06-30$1.31 → $1.75 (+34.4% total)-26.63%2021-06-30 → 2026-06-30$8.25 → $1.75 (-78.7% total)n/a
Price: +37.86%2025-10-16 → 2026-10-16$20.91 → $28.82 (+37.8% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.+97.22%2023-10-16 → 2026-10-16$3.76 → $28.82 (+667.5% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.+5.28%2021-10-15 → 2026-10-16$22.28 → $28.82 (+29.4% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.n/a
Total return: +37.86%2025-10-16 → 2026-10-16$20.91 → $28.82 (+37.8% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.+97.22%2023-10-16 → 2026-10-16$3.76 → $28.82 (+667.5% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.+5.28%2021-10-15 → 2026-10-16$22.28 → $28.82 (+29.4% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.n/a

Fundamentals end at the last reported quarter; price and total return end at the latest close.

Valuation

P/E (ttm)Price ÷ TTM diluted EPS. Net income carries everything below the operating line, including one-off gains. Negative when the trailing year lost money.: 133.0×2020-03 -17.952026-10 127.11-808.2% over the window
Fwd P/E: 19.5×
P/S (ttm)Market cap ÷ TTM revenue.: 7.8×2022-09 1605.972026-10 7.81-99.5% over the window
P/B (mrq)Market cap ÷ stockholders' equity at the most recent quarter end.: 16.4×2020-03 4.702026-10 16.43+249.6% over the window
P/FCF (ttm)Market cap ÷ TTM free cash flow (operating cash flow − capex).: 92.5×2020-03 -19.972026-10 92.59-563.6% over the window
EV/Sales (ttm): 8.0×
FCF yield (ttm)TTM free cash flow ÷ market cap — the inverse of P/FCF.: 1.08%2019-12 -3.8%2026-06 1.2%-131.3% over the window
Buyback yield (realized, 1y)1 − shares_at(2026-06-30) ÷ shares_at(2025-06-30) = 1 − 125.7M ÷ 119.9M. Point-in-time share counts from the company's own SEC filings (the same count at both ends), published only when the cash flow statement shows repurchases inside that window. A falling price can't inflate it; negative means net dilution.: -4.83%
Shareholder yield (realized, 1y)Buyback leg + dividend leg: shares retired over the year (-4.83%) + dividends paid over that year ($0) ÷ market_cap_at(2025-06-30) ($1.7B). Both legs are measured against the start of the window, so a payout can't shrink its own denominator.: -4.83%
Buyback yield (cash, ttm)Buybacks net of issuance over the trailing twelve months ($0) ÷ today's market cap ($3.6B). Dollars SPENT over what the company is worth NOW — a stock that fell after buying reads high.: 0.00%2019-12 0.0%2026-06 0.0%
Shareholder yield (cash, ttm)(TTM buybacks net of issuance $0 + TTM dividends $0) ÷ today's market cap ($3.6B). Same caveat as the cash buyback yield.: 0.00%2019-12 0.0%2026-06 0.0%

Vs own 10Y history

P/S: 28th
P/B: 94th

Bar = where today’s multiple sits in ARQT’s own 10-year range:near a decade-low (cheap)→near a decade-high (rich).

Performance · price return · as of 2026-10-16#

-0.96%

+8.43%

+10.25%

+3.89%

YTD

-0.76%

+37.83%

+29.35%

Financial statements

Open full ARQT financials →

Loading financial statements…

Ticker	Name	1M	1D
LLY	Eli Lilly and Company	+10.48%	+0.43%
JNJ	Johnson & Johnson	-4.38%	+0.90%
ABBV	AbbVie Inc.	+8.73%	+0.71%
UNH	UnitedHealth Group Incorporated Common Stock (DE)	+6.97%	-1.29%
MRK	Merck & Co. Inc.	+0.72%	+0.52%
NVS	Novartis AG	+8.59%	+0.16%
TMO	Thermo Fisher Scientific Inc.	+6.41%	-0.93%
AMGN	Amgen Inc.	+14.92%	-0.35%

ARQT — Arcutis Biotherapeutics Inc. price, chart and key statistics